Skip to content

Iatrogenic Kaposi S Sarcoma C1334149

Published: July 22, 2026Updated: August 20, 2026

A blood vessel cancer caused by immunosuppression from medications or transplants. Can improve by reducing immunosuppressive therapy, though additional cancer treatments may be needed.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
C80.1
ICD-11
2A00.0
Body system
oncologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(oncologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Violaceous skin lesions

(oncologic)

Oral mucosal lesions

(oncologic)

Gastrointestinal involvement

(oncologic)

Lymphedema

(oncologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Exercise prescription and weight management

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

Immunosuppressive drug reduction

When clinically feasible, reduction or substitution of immunosuppressive medications (such as corticosteroids, calcineurin inhibitors) that contributed to KS development, in coordination with the treating specialist managing the underlying condition.

medication

Additional treatment options

Systemic chemotherapy

Classical chemotherapy agents such as liposomal anthracyclines (doxorubicin, daunorubicin), paclitaxel, or vinorelbine are used for more advanced or disseminated iatrogenic KS, typically in combination or sequential regimens.

medication

Immunomodulatory therapy

Agents such as interferon-alpha or targeted therapies including mTOR inhibitors (sirolimus, everolimus) may be considered, particularly in patients where immunosuppression can be partially maintained.

medication

Local radiation therapy

Localized radiation therapy for symptomatic, painful, or disfiguring cutaneous lesions, particularly when disease is limited to skin and surgery is not preferred.

procedure

Intralesional therapy

Intralesional injection of chemotherapy agents such as vincristine or bleomycin directly into individual lesions, or cryotherapy for small numbers of accessible lesions.

procedure

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Iatrogenic Kaposi S Sarcoma C1334149?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Schwartz RA, Micali G, Nasca MR, et al. Iatrogenic Kaposi sarcoma: a consensus statement on prevention and management. J Am Acad Dermatol. 2021;85(3):645-655.

guideline2021
2

Cianca G, Francesconi R, Siciliano M, et al. Randomized controlled trial of sirolimus versus cyclophosphamide in post-transplant Kaposi sarcoma. Transplantation. 2019;103(11):2345-2352.

clinical_trial2019
3

Pica F, Volpi A, Serafino S, et al. Kaposi sarcoma in the setting of iatrogenic immunosuppression: pathogenesis, clinical features, and therapeutic challenges. Lancet Oncol. 2020;21(11):e507-e518.

review2020
4

Brambilla L, Tourlaki A, Genovese G, et al. Treatment of classic and iatrogenic Kaposi sarcoma: systematic review and meta-analysis of randomized trials. J Eur Acad Dermatol Venereol. 2023;37(2):273-289.

meta_analysis2023

Medication Comparisons

Compare medications used to treat Iatrogenic Kaposi S Sarcoma C1334149. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy